The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
This study has been completed.
Eli Lilly and Company
Information provided by (Responsible Party):
First received: October 7, 2006
Last updated: August 21, 2012
Last verified: August 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||August 2011|
|Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||November 10, 2011|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28.